MedPath

Effect of Teriparatide, Alendronate, and Zoledronic Acid on treatment of secondary osteoporosis

Phase 2
Conditions
Secondary osteoporosis.
Osteoporosis with pathological fracture
Registration Number
IRCT201605159014N98
Lead Sponsor
Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
120
Inclusion Criteria

(a) secondary osteoporosis; (b) T-score less than -2.5 in the lumbar spine or femoral neck.
Exclusion criteria: (a) primary osteoporosis; (b) using prednisolone more than 3 months; (c) rheumatologic disease; (d) malignancy; (e) hypothyroidism; (f) renal failure; (g) history of surgery of parathyroid gland.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Assessing the bone density. Timepoint: before treatment and one year later. Method of measurement: using Dual X-ray Absorptiometry.
Secondary Outcome Measures
NameTimeMethod
Assessing the bone density. Timepoint: before treatment and one year later. Method of measurement: using T-score.
© Copyright 2025. All Rights Reserved by MedPath